GSK corporate headquarters in Brentford, London. Credit: GSK / Flickr.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for GSK and Vir Biotechnology’s investigational Covid-19 therapy, Xevudy (sotrovimab).

The neutralising monoclonal antibody has been authorised to treat symptomatic mild-to-moderate Covid-19 adults and adolescents aged 12 years and above, who are at high risk of developing severe disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Prior to granting the authorisation, the MHRA and the Commission on Human Medicines rigorously reviewed the quality, efficacy and safety of the Covid-19 drug.

MHRA’s authorisation was based on the data obtained from the Phase III COMET-ICE trial conducted on 1,057 participants.

It was observed that the drug reduced 79% of hospitalisation and death risk in mild-to-moderate Covid-19 adult patients.

The UK regulator has recommended administering Xevudy (sotrovimab) within five days of Covid-19 symptoms onset in the early stages of infection.

GSK Europe senior vice-president George Katzourakis said: “The conditional marketing authorisation in Great Britain, coupled with the supply agreement, is a testament to the critical need to make sotrovimab available in the UK as the pandemic continues to progress.

“We believe it is important to ensure that we have treatments ready and available, especially early treatment options, for a broad group of patients at increased risk of progressing to severe Covid-19.”

The authorisation allows the availability of the drug in Wales, England and Scotland.

Incorporating Xencor’s Xtend technology, sotrovimab binds to an epitope on the SARS-CoV-2 virus to delay resistance development.

The antibody can achieve increased concentration in the lungs for penetrating into Covid-19-affected airway tissues and increasing antibody elimination half-life.

Last month, GSK and Vir Biotechnology secured contracts from the US Government to deliver sotrovimab doses for nearly $1bn.